JACOBS-HOLDING-AG
17.4.2024 11:06:32 CEST | Business Wire | Press release
Jacobs Holding today announced that the board of directors has appointed Timothy Franks as Chief Executive Officer effective May 1, 2024.
With an impressive 25-year career at two prominent investment firms, Tim brings extensive experience and a proven track record in global private equity. His most recent role was as a Partner and Co-CEO of the democratized private equity business at KKR. He played a pivotal role in building KKR’s European franchise, leading the EMEA Core strategy, and overseeing the development of activities in the UK & Ireland, as well as the Consumer industry team in EMEA. Prior to that, Tim spent 17 years at Advent International, where he notably opened and led the New York office from 2010 to 2013. Throughout his tenure at both firms, he held various chair and board positions at portfolio companies.
Under his leadership, Jacobs Holding aims at further strengthening its investment activities, particularly in the services, healthcare and consumer industries. Tim’s strong investment focus on helping businesses with their sustainability and digitalization goals will be pivotal for Jacobs Holding in consolidating its investment approach, and investing in the growth potential of existing and future portfolio companies.
Nicolas and Philippe Jacobs, Co-Chairmen commented: “We are excited to have Tim join Jacobs Holding. Beyond being a highly accomplished private equity manager with an impressive track record, he has proven himself as a strong leader. Tim possesses all the qualities needed to get Jacobs Holding to the next level as a sustainable and entrepreneurial investor.”
Timothy Franks commented: “I look forward to working with the Jacobs team. It will be a real privilege to lead Jacobs Holding, given the strong purpose of the firm and its investment approach, which intersects three investment trends in alternative asset management: focusing on direct investments, pursuing a long-term investment horizon, and bringing sustainability and digitalization to the core of its activities.”
About Jacobs Holding AG
Jacobs Holding is a global professional investment firm founded by late entrepreneur Klaus J. Jacobs, in which he bundled his entrepreneurial activities in 1994. Jacobs Holding invests with a long-term horizon in companies active in non-cyclical businesses which already have or aim for a leading market position and have further growth and value creation potential. The current portfolio of Jacobs Holding consists of Cognita (www.cognita.com), Colosseum Dental Group (www.colosseumdental.com), North American Dental Group (www.nadentalgroup.com) as well as a large stake in the publicly traded company Barry Callebaut AG (www.barry-callebaut.com). The sole economic beneficiary of Jacobs Holding is the Jacobs Foundation, one of the world's leading charitable foundations for the promotion of development opportunities for children and young people. Since the foundation was established in 1989, around CHF 800 million has been paid out cumulatively.
Additional features:
File: JAG_CEO_English
File: Picture Timothy Franks
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417007318/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom